Yubo International Biotech Limited
Yubo International Biotech Limited, through its subsidiaries, focuses on the research, development, and application of endometrial stem cells. The company offers healthcare products for respiratory system, skincare products, hair care products, healthy beverages, and male and female personal care products; and stem cell related services, including cell testing and health management consulting ser… Read more
Yubo International Biotech Limited (YBGJ) - Net Assets
Latest net assets as of September 2025: $-1.60 Million USD
Based on the latest financial reports, Yubo International Biotech Limited (YBGJ) has net assets worth $-1.60 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($953.21K) and total liabilities ($2.56 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-1.60 Million |
| % of Total Assets | -168.07% |
| Annual Growth Rate | N/A |
| 5-Year Change | -382.43% |
| 10-Year Change | N/A |
| Growth Volatility | 1511.05 |
Yubo International Biotech Limited - Net Assets Trend (2002–2024)
This chart illustrates how Yubo International Biotech Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Yubo International Biotech Limited (2002–2024)
The table below shows the annual net assets of Yubo International Biotech Limited from 2002 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-3.30 Million | -78.86% |
| 2023-12-31 | $-1.84 Million | -226.10% |
| 2022-12-31 | $-565.37K | -330.93% |
| 2021-12-31 | $-131.20K | -111.24% |
| 2020-12-31 | $1.17 Million | +164.94% |
| 2019-12-31 | $-1.80 Million | -8.05% |
| 2018-12-31 | $-1.66 Million | -9.76% |
| 2017-12-31 | $-1.52 Million | -10.50% |
| 2016-12-31 | $-1.37 Million | -9.06% |
| 2015-12-31 | $-1.26 Million | -2.44% |
| 2014-12-31 | $-1.23 Million | -11.43% |
| 2013-12-31 | $-1.10 Million | -21.63% |
| 2012-12-31 | $-906.00K | -12.83% |
| 2011-12-31 | $-803.00K | -11.68% |
| 2010-12-31 | $-719.00K | -18.06% |
| 2009-12-31 | $-609.00K | -16.44% |
| 2008-12-31 | $-523.00K | -34.79% |
| 2007-12-31 | $-388.00K | -25.97% |
| 2006-12-31 | $-308.00K | -58.76% |
| 2005-12-31 | $-194.00K | +31.45% |
| 2004-12-31 | $-283.00K | -55.49% |
| 2003-12-31 | $-182.00K | -3133.33% |
| 2002-12-31 | $6.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Yubo International Biotech Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2030318800.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $119.82K | % |
| Other Comprehensive Income | $127.04K | % |
| Other Components | $2.99 Million | % |
| Total Equity | $-3.42 Million | 100.00% |
Yubo International Biotech Limited Competitors by Market Cap
The table below lists competitors of Yubo International Biotech Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Baiya International Group Inc. Ordinary Shares
NASDAQ:BIYA
|
$740.45K |
|
Osteopore Ltd
AU:OSX
|
$740.73K |
|
Signet International Holdings Inc
PINK:AQPW
|
$740.86K |
|
Core Assets Corp
OTCQB:CCOOF
|
$741.32K |
|
2U, Inc.
PINK:TWOUQ
|
$739.61K |
|
Kedaung Indah Can Tbk
JK:KICI
|
$739.07K |
|
Public Service Company of New Mexico PFD 4.58%
PINK:PNMXO
|
$738.54K |
|
Anagenics Ltd
AU:AN1
|
$738.39K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Yubo International Biotech Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -1,843,703 to -3,424,465, a change of -1,580,762.
- Net loss of 1,775,303 reduced equity.
- Other comprehensive income increased equity by 127,044.
- Other factors increased equity by 67,497.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-1.78 Million | -51.84% |
| Other Comprehensive Income | $127.04K | +3.71% |
| Other Changes | $67.50K | +1.97% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Yubo International Biotech Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2002-12-31 | $0.01 | $0.05 | x |
| 2003-12-31 | $-0.24 | $0.05 | x |
| 2004-12-31 | $-0.38 | $0.05 | x |
| 2005-12-31 | $-0.23 | $0.05 | x |
| 2006-12-31 | $-0.28 | $0.05 | x |
| 2007-12-31 | $-0.36 | $0.05 | x |
| 2008-12-31 | $-0.46 | $0.05 | x |
| 2009-12-31 | $-0.52 | $0.05 | x |
| 2010-12-31 | $-0.61 | $0.05 | x |
| 2011-12-31 | $-0.68 | $0.05 | x |
| 2012-12-31 | $-0.77 | $0.05 | x |
| 2013-12-31 | $-0.93 | $0.05 | x |
| 2014-12-31 | $-1.04 | $0.05 | x |
| 2015-12-31 | $-1.07 | $0.05 | x |
| 2016-12-31 | $-1.16 | $0.05 | x |
| 2017-12-31 | $-1.29 | $0.05 | x |
| 2018-12-31 | $-1.41 | $0.05 | x |
| 2019-12-31 | $-1.52 | $0.05 | x |
| 2020-12-31 | $0.01 | $0.05 | x |
| 2021-12-31 | $0.00 | $0.05 | x |
| 2022-12-31 | $0.00 | $0.05 | x |
| 2023-12-31 | $-0.02 | $0.05 | x |
| 2024-12-31 | $-0.03 | $0.05 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Yubo International Biotech Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -51161.47%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-2207.00%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2002 | -50700.00% | 0.00% | 0.00x | 135.17x | $-3.04 Million |
| 2003 | 0.00% | 0.00% | 0.00x | 0.00x | $-191.80K |
| 2004 | 0.00% | 0.00% | 0.00x | 0.00x | $-100.97 Million |
| 2005 | 0.00% | 0.00% | 0.00x | 0.00x | $-70.60K |
| 2006 | 0.00% | 0.00% | 0.00x | 0.00x | $-83.20K |
| 2007 | 0.00% | 0.00% | 0.00x | 0.00x | $51.80K |
| 2008 | 0.00% | 0.00% | 0.00x | 0.00x | $-92.70K |
| 2009 | 0.00% | 0.00% | 0.00x | 0.00x | $-25.10K |
| 2010 | 0.00% | 0.00% | 0.00x | 0.00x | $-38.10K |
| 2011 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.70K |
| 2012 | 0.00% | -158.46% | 4.33x | 0.00x | $-12.40K |
| 2013 | 0.00% | -176.67% | 7.50x | 0.00x | $4.20K |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $6.80K |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.20K |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-86.80K |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $7.60K |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $18.40K |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $45.80K |
| 2020 | -60.96% | -52.58% | 0.55x | 2.09x | $-828.57K |
| 2021 | 0.00% | -123.92% | 0.27x | 0.00x | $-1.53 Million |
| 2022 | 0.00% | -1155.28% | 0.04x | 0.00x | $-1.15 Million |
| 2023 | 0.00% | -197.64% | 0.36x | 0.00x | $-1.01 Million |
| 2024 | 0.00% | -51161.47% | 0.00x | 0.00x | $-1.43 Million |
Industry Comparison
This section compares Yubo International Biotech Limited's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $2,683,526,542
- Average return on equity (ROE) among peers: -32.48%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Yubo International Biotech Limited (YBGJ) | $-1.60 Million | -50700.00% | N/A | $740.35K |
| ANGELALIGN TECHNOLOGY INC (AGLFF) | $480.24 Million | 2.52% | 0.41x | $405.57 Million |
| Akoya Biosciences Inc (AKYA) | $-30.16 Million | 0.00% | 0.00x | $16.24 Million |
| Alcon AG (ALC) | $19.68 Billion | 1.70% | 0.48x | $37.82 Billion |
| Align Technology Inc (ALGN) | $3.85 Billion | 10.94% | 0.61x | $11.75 Billion |
| AngioDynamics Inc (ANGO) | $355.71 Million | 3.06% | 0.15x | $354.40 Million |
| Ansell Limited (ANSLF) | $386.33 Million | -0.45% | 0.87x | $2.58 Billion |
| AptarGroup Inc (ATR) | $2.07 Billion | 11.57% | 1.03x | $8.27 Billion |
| AtriCure Inc (ATRC) | $72.60 Million | -15.79% | 0.54x | $1.42 Billion |
| Avinger Inc (AVGR) | $-35.69 Million | 0.00% | 0.00x | $1.26 Million |
| Anteris Technologies Global Corp. Common Stock (AVR) | $9.03 Million | -338.35% | 0.77x | $156.14 Million |